GlassScriptPhysician profile
Michelle Rainey
NPI 1558958983
$9,670.35
in general payments reported to CMS, 2019-2025
33 companies · $2,729 in 2025
The $2,729 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $710 · 2022: $923 · 2023: $2,662 · 2024: $2,645 · 2025: $2,729.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $5,412 · Food and Beverage: $2,625.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $5,412.45 |
| Food and Beverage | $2,624.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $5,431.45 | 2022-2025 | Da Vinci Surgical System |
| Abbvie INC. | $919.14 | 2021-2025 | |
| Novo Nordisk INC | $843.20 | 2021-2024 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $339.09 | 2021-2024 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $336.65 | 2021-2024 | Jardiance, Synjardy |
| Glaxosmithkline, LLC. | $266.15 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $250.46 | 2022-2024 | |
| Exact Sciences Corporation | $188.09 | 2023-2024 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $173.77 | 2021-2024 | Xarelto, Spravato |
| Alkermes, INC. | $148.65 | 2022-2024 | Vivitrol, Vivitrol |
| Astellas Pharma US INC | $129.78 | 2021-2024 | Veozah |
| Astrazeneca Pharmaceuticals LP | $63.90 | 2021-2024 | Breztri, Airsupra |
| Biohaven Pharmaceutical Holding Company LTD. | $53.83 | 2022 | |
| Merck Sharp & Dohme LLC | $49.71 | 2021-2024 | Capvaxive, Gardasil, Gardasil 9 |
| Otsuka America Pharmaceutical, INC. | $42.31 | 2023 | Rexulti |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $42.20 | 2023-2024 | Gvoke Hypopen |
| Phathom Pharmaceuticals, INC. | $36.36 | 2024 | Voquezna |
| Amgen INC. | $32.88 | 2022-2024 | Otezla, Repatha |
| Dexcom, INC. | $31.60 | 2024 | Dexcom G6 Transmitter |
| Shield Therapeutics INC | $30.88 | 2023 | Accrufer |
| Mylan Pharmaceuticals INC. | $27.68 | 2022 | |
| Hologic Sales and Service, LLC | $25.78 | 2025 | Aptima |
| Bausch Health US, LLC | $24.77 | 2022 | |
| Axsome Therapeutics, INC. | $22.22 | 2024 | Auvelity |
| Esperion Therapeutics, INC. | $21.86 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $21.10 | 2021 | |
| Antares Pharma, INC. | $21.06 | 2024 | Xyosted |
| Arbor Pharmaceuticals, INC. | $20.42 | 2021 | |
| Lundbeck LLC | $19.08 | 2024 | Rexulti |
| Gilead Sciences, INC. | $16.20 | 2021 | |
| Sanofi-Aventis U.S. LLC | $14.68 | 2021 | |
| Idorsia Pharmaceuticals US INC | $13.08 | 2023 | Quviviq |
| Eisai INC. | $12.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Rainey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.